AbbVie’s earnings did the bare minimum—and then some

Earnings season, but make it slightly boring

AbbVie just turned in a classic “fine, we’ll take it” quarter. Non-GAAP EPS landed at $1.15, right on the money, while revenue came in at $11.16 billion — about $160 million above forecasts. In other words: no fireworks, but no face-plant either.

Why investors are still paying attention

That matters because AbbVie is one of those giant healthcare names where stability is the whole point. If you’re holding it, you’re not exactly begging for viral growth tweets — you want the cash machine to keep humming. Beating on revenue while matching EPS is a decent way to keep that narrative intact.

The messy parts don’t disappear

The company is still dealing with some headaches in its Nutrition segment, so this wasn’t a flawless victory lap. But the big picture is still pretty straightforward: the portfolio is broad, the market cap is enormous, and the business continues to throw off enough operating strength to stay interesting.

The investor takeaway

There’s also a little extra spice here: the article notes $9.5 million of insider sales over the past three months. That doesn’t scream panic, but it does give you the usual “hmm” eyebrow raise.

Big picture: AbbVie didn’t deliver a moonshot, but it did enough to keep the stock’s case from getting awkward.